Advertisement · 728 × 90
#
Hashtag
#CTOS2025
Advertisement · 728 × 90
Post image

CTOS was packed with big conversations. Our new webinar cuts to the good stuff — key studies, emerging trends, and why it matters for patients. Watch the replay.
bit.ly/CTOS2025-REC
#GISTEducation #CTOS2025 #GIST

0 0 0 0
Video

Discover the latest breakthroughs in #GISTresearch! Dr. Sobczuk from Vall d’Hebron Institute of Oncology will unpack key findings and trends shared at the #CTOS2025 Annual Meeting, offering valuable insights for the #GISTcommunity. bit.ly/CTOS-updates #GISTEducation #GIST

0 0 0 0
Post image

From breakthroughs to new data, #CTOS2025 brought vital updates for the #GISTcommunity. Dr. Sobczuk will guide us through the highlights and what they mean for patients, clinicians, and advocates. bit.ly/CTOS-updates #GISTEducation #GIST

0 0 0 0

Last week Sarcoma UK joined CTOS in Boca Raton, where Robin Jones shared promising phase 2 ChonDRAgon results for people with unresectable or metastatic chondrosarcoma.

#CTOS2025

0 0 1 0
Post image

At #CTOS2025 Sr. Dir. of Research Denisse Evans presented pediatric and young adult data from the LRG Patient Registry, emphasizing the importance of mutational testing and timely surgery for improving outcomes. #PatientReportedData

0 0 0 0
Scientist at lectern with slide reading "Q&A"

Scientist at lectern with slide reading "Q&A"

Conclusion slide: • Intact IGF1/PPARG2 in WDLPS
• PPARG2 restores differentiation
in DDLPS
GLP1 signaling is the dominant, druggable epigenetic program in DDLPS Induces increased expression of adipose markers
Identifying chromatin modifiers at the PPARG2 TSS
Fully characterizing GLP1-induced differentiation and other cellular processes modified through this axis

Conclusion slide: • Intact IGF1/PPARG2 in WDLPS • PPARG2 restores differentiation in DDLPS GLP1 signaling is the dominant, druggable epigenetic program in DDLPS Induces increased expression of adipose markers Identifying chromatin modifiers at the PPARG2 TSS Fully characterizing GLP1-induced differentiation and other cellular processes modified through this axis

Exciting end to #CTOS2025 with final presentation from Erica Pimenta. Could PPARγ-2 or GLP1 agonists restore differentiation in dedifferentiated liposarcoma?

6 1 0 0
Post image

Deeply honored to receive the Brian Van Tine Memorial Peer Recognition Award for Excellence in LMS Research from the National Leiomyosarcoma Foundation presented at #CTOS2025. I am grateful to the entire LMS Roundtable community, as well as Mitch and Annie Achee for their unwavering support.

2 0 1 0
Preview
Herbert Loong: Building Global Sarcoma Connections at CTOS 2025 - OncoDaily Herbert Loong: Building Global Sarcoma Connections at CTOS 2025 / CTOS, CTOS2025, Herbert Loong, Meng Xu Welliver, sarcoma

Building Global Sarcoma Connections at CTOS 2025 - Herbert Loong

@herbloongmd.bsky.social

oncodaily.com/voices/409198

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CTOS #CTOS25 #CTOS2025

3 0 0 0
Video

Day 2 highlights #CTOS2025 w/Exec. Dir. Sara Rothschild, Sr. Dir. Data Mgmt & Research Denisse Evans, & Data Analyst Jerry Call, discussing LRG posters with GIST researchers, & oncologists. Register for Updates from CTOS w/ Dr. Sobczuk bit.ly/CTOS-updates #GISTResearch #PatientReportedData

1 0 0 0
Video

Executive Director Sara Rothschild is representing the Liposarcoma Support Network at the #CTOS2025 Annual Meeting, connecting with leading sarcoma experts and highlighting our growing advocacy and research initiatives.

1 1 0 0
Post image Post image Post image

Can adding aromatase inhibitor (+/-LHRHa) rescue patients with #PEComa who progress after responding to mTOR inhibitor? #CTOS2025

- n=23 women
- 26% PR, 35% SD
- Time to progression generally shorter than initial mTORi response
- Some exceptions in patients with TSC1/TSC2/PTEN

0 0 0 0
Man at lectern smiling

Man at lectern smiling

ChonDRAgon study design. Patients allowed to crossover to ozekibart at progression

ChonDRAgon study design. Patients allowed to crossover to ozekibart at progression

KM curve with PFS at 12 mo of 21.7%

KM curve with PFS at 12 mo of 21.7%

Tornado plot of TRAE with fatigue, diarrhea, nausea, and elevated LFTs highest

Tornado plot of TRAE with fatigue, diarrhea, nausea, and elevated LFTs highest

.@RobinL_Jones @royalmarsden presenting ChonDRAgon PhII registrational study of Ozekibart in conventional #chondrosarcoma #CTOS2025.

- No approved systemic therapies
- mPFS 5.5 mo, with 21.7% w/o prog @ 12 mo
- Activity in both IDH-WT & mut
- TRAE incl ~13% fatigue, ~6% hepatitis

2 0 0 0
List of sites and prior treatment lines for patients enrolled. All patients had received both chemotherapy and checkpoint inhibition.

List of sites and prior treatment lines for patients enrolled. All patients had received both chemotherapy and checkpoint inhibition.

Receding scalp lesion shown in photographs

Receding scalp lesion shown in photographs

Multiple receding lesions shown.

Multiple receding lesions shown.

#CTOS2025 Need options for pts w/ angiosarcoma who are refractory to ICI. In PhI, injected oncolytic virus w/ TGF-B trap (AdAPT-001) shows some efficacy! Notably heavily pre-tx group.

1 0 0 0
Waterfall plot of change in max lesion size among patients with TRK fusion sarcomas who had a 2+ year response

Waterfall plot of change in max lesion size among patients with TRK fusion sarcomas who had a 2+ year response

Larotrectinib for TRK-fusion sarcomas: when it works, it works.

- 38% long-term (2 year) responders
- In responders, 73% remain without progression at 6 years, 98% OS

#CTOS2025 Next questions: When to stop? How to predict responders?

3 0 0 0
A picture of the Boca Raton behind palm trees.

A picture of the Boca Raton behind palm trees.

A golf course framed by palm trees and a beautiful sky.

A golf course framed by palm trees and a beautiful sky.

Notably different weather vibes down here in Boca Raton for #CTOS2025 compared to snow storms in Chicago.

2 0 0 0
Post image

Dr. Matthew Hemming presented his research at #CTOS2025 on exploiting metabolic dysregulation in SDH-deficient GIST, offering valuable insights into new strategies that may advance treatment options for this rare subtype. @sarcomalab.bsky.social
#GIST #SDHGIST #SarcomaResearch

2 1 0 0
Post image

LSN is at #CTOS2025! Visit the Patient Advocacy Lounge to see our poster highlighting the global patient campaign urging @boehringerglobal.bsky.social to continue development of brigimadlin for sarcoma patients. #liposarcoma #SaveBrigimadlin #SignThePetition brigimadlinpetition.org

2 0 0 0
A photograph of the CTOS 2025 Annual Meeting poster at the front of the Boca Raton resort in Florida.

A photograph of the CTOS 2025 Annual Meeting poster at the front of the Boca Raton resort in Florida.

Viqui, a member of the Bone Cancer Research Trust team, standing in front of a poster about long-term and late effects research carried out by the charity.

Viqui, a member of the Bone Cancer Research Trust team, standing in front of a poster about long-term and late effects research carried out by the charity.

We're representing the bone cancer community at the Connective Tissue Oncology Society (CTOS) annual meeting 🌴

Over the next three days, world-leading clinicians, researchers and advocates will come together to advance bone cancer and sarcoma research 🔬

#CTOS2025 #Research #UntilTheresACure

0 0 1 0
Video

The Life Raft Group is proud to have a strong scientific presence at #CTOS2025. Executive Director Sara Rothschild and Sr. Director of Data Management Denisse Evans are presenting our latest patient registry research through posters, a presentation, and collaboration. #GISTresearch

0 0 0 0
Post image

At #CTOS2025, Denisse Evans, MS, presents “Survival Outcomes and Molecular Heterogeneity in Early-Onset GIST” Sat. 11/15 - Royal Palm Ballroom, 2:45–3:45 PM. The LRG also has three posters on display discussing survival outcomes #GIST #SarcomaResearch #GISTresearch

1 0 0 0
Preview
Herbert Loong: Long Journey to CTOS 2025 in Boca Raton - OncoDaily Herbert Loong: Long Journey to CTOS 2025 in Boca Raton / cancer, CTOS, CTOS 2025, Herbert Loong, OncoDaily, Oncology

Long Journey to CTOS 2025 in Boca Raton - Herbert Loong

@herbloongmd.bsky.social

oncodaily.com/voices/ctos-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CTOS #CTOS2025

4 0 0 0
Post image

🎗️ Attending #CTOS2025? Don’t miss the Foundational Science of Sarcomas Symposium!

This year’s highlights include sessions on
🔹 Cancer Metabolism & Drug Development
🔹 AI Applications in Sarcoma Diagnostics & Care
🔹 Publishing Your Research — In Conversation with Editors of Leading Oncology Journals

2 1 0 0
Post image

When that #CTOS2025 email hits 🎉🎉🎉🎉🎉 Very excited to represent TGCT Support at CTOS and present on #TGCT.

I’d like to thank my co-authors 👏🏻👏🏻

1 0 0 0